Clinical Trials · NCT06635057
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 166
- Start date
- Oct 2024
- Locations
- 29 sites, Saudi Arabia, United Arab Emirates
- Primary endpoint
- Change from Baseline in Hemoglobin A1c (HbA1c)